Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add filters








Language
Year range
1.
Article | IMSEAR | ID: sea-200952

ABSTRACT

Background:Malnutrition is common in patients with cancer, whichadversely affectsthesurvival and quality of life ofcancer patients.However, there is no national data on the prevalence of malnutrition inChinese cancer patients. Thisstudy aims to evaluate the prevalenceof malnutrition and quality of life(QOL)ofChinese patients with localregional, recurrentor metastatic cancer,to address the prognostic value of nutritional status and QOLon the survival of cancer patients in China and to validate the patient-generated subjective global assessment (PG-SGA) questionnaire in Chinese cancer patients.Methods:Thisisanobservational,multi-centered,and hospital-based prospective cohort study.We aimed to recruit 50,000 cancer patients (age 18and above)overan 8-year period.Data collection will occur within 48hrafter patientsare admitted to hospital, 30-days after hospital admission, and the follow-up will be conducted1-8years after enrolment. The primary outcomeisoverall survival, and secondaryoutcomes arelength of hospital stay and hospital costs. Factors measured are demographic characteristics, tumor characteristics, anthropometry measurements,hematological measurement, body composition, PG-SGAscores,Karnofsky performance status scores,and QLQ C30 scores. This protocol wasapproved by local ethical committees of all the participant hospitals.Conclusions: This multi-centered, large-scale, long-time follow-up prospective study will help diagnose malnutrition in cancer patients in China, and identify the related risk factors associated with the negative outcomes. The anticipated results will highlight the need for a truly scientific appraisal of nutrition therapy, and help to improve outcomes among cancer patients in China.Trial Registration: The trial has been registered with the Chinese Clinical Trial Registry, ChiCTR1800020329. Registered on 19 December 2018

2.
Journal of International Oncology ; (12): 107-111, 2020.
Article in Chinese | WPRIM | ID: wpr-863442

ABSTRACT

Radiation pneumonitis is a common complication in the radiotherapy for thoracic malignant tumors. And the resulting respiratory failure is one of the most serious side effects. The occurrence and severity of radiation pneumonitis depend on many factors such as age, performance status scores, smoking status, lung condition, tumor sizes, tumor location, chemoradiotherapy related factors, inflammatory factors and single-nucleotide polymorphism, et al. Some imaging examinations, for example single-photon emission computed tomography and PET-CT, have been used to predict radiation pneumonitis, while its usefulness remains to be strengthened. Further researches are still needed to find the gold standard in the prediction of radiation pneumonitis.

3.
Journal of International Oncology ; (12): 109-112, 2019.
Article in Chinese | WPRIM | ID: wpr-743100

ABSTRACT

Lung cancer has been the most dangerous malignant tumor in the worldwide.Nowadays,for patients with resectable early or local advanced non-small cell lung cancer (NSCLC),both domestic and foreign guidelines recommended multidisciplinary treatments like surgery,chemotherapy and radiotherapy.Recent studies have shown that neoadjuvant chemotherapy can significantly improve the prognosis of patients with resectable NSCLC and has better treatment compliance and tolerance.

4.
Journal of International Oncology ; (12): 561-565, 2018.
Article in Chinese | WPRIM | ID: wpr-693555

ABSTRACT

Cisplatin and nedaplatin have been proved to be effective for most of solid tumors including head and neck cancer,esophageal cancer,lung cancer,bladder cancer,ovary epithelial cancer,testicular cancer and cervical cancer. Nedaplatin is often used as an alternative to cisplatin in Asia. However,the evi-dence from phase Ⅲ clinical trials is insufficient. Clinicians should be cautious when using nedaplatin to re-place cisplatin.

SELECTION OF CITATIONS
SEARCH DETAIL